Pharmaceutical - Kalydeco

Filter

Current filters:

Kalydeco

Popular Filters

Report: Global cystic fibrosis market value to treble by 2019

12-03-2014

The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

Vertex reports fifth consecutive quarter of losses; updates on Kalydeco

30-07-2013

US biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) has reported second quarter revenues of $311 million,…

FinancialIncivekIncivoKalydecoNorth AmericaPharmaceuticalVertex

Vertex receives first two Breakthrough Therapy Designations from US FDA

10-01-2013

During its presentation at the JP Morgan annual health care conference, US drugmaker Vertex Pharmaceuticals…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertexVX-809

Vertex' hep C drug Incivek to carry boxed warning in USA; UK to fund Kalydeco

20-12-2012

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the label on its new hepatitis C drug Incivek…

Anti-viralsEuropeIncivekKalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

03-12-2012

Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis

29-10-2012

Scientists at the Hospital for Sick Children in Toronto, Canada, have established that a drug recently…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-770

FDA warns on possible cataract risk with Vertex' Kalydeco

31-08-2012

The US Food and Drug Administration this week notified health care professionals, parents/caregivers…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco

30-07-2012

Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

Vertex tumbles despite good final data on combo cystic fibrosis therapy

01-07-2012

USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-809

Vertex slumps as firm revises Kalydeco data

30-05-2012

The USA's Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

EMA recommends approval of Vertex' CF drug Kalydeco

28-05-2012

European Medicines Agency last Friday recommended approval of Kalydeco (ivacaftor), an orphan-designated…

EuropeKalydecoPharmaceuticalRare diseasesRegulationRespiratory and PulmonaryVertex

FDA approves combo diabetes drug Jentadueto and Kalydeco

01-02-2012

The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets,…

Boehringer IngelheimDiabetesEli LillyJentaduetoKalydecolinagliptinNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Vertex plans for Kalydeco launch

09-01-2012

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) announced its 2012 business objectives in conjunction…

Anti-viralsIncivekKalydecoPharmaceuticalRare diseasesRegulationResearchVertex

Vertex updates on US and EU Kalydeco filings; to get new CEO

16-12-2011

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the US Food and Drug Administration has…

EuropeKalydecoManagementNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis

06-11-2011

The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Vertex files for US priority review and approval of Kalydeco for cystic fibrosis

20-10-2011

USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) says it has filed a New Drug Application with the Food…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Company Spotlight

ImmunoGen

ImmunoGen

Back to top